Vivimed Labs Ltd (VIVIMEDLAB) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

9.34 k (1,484.12%) Volume

Shareholding (Sep 2023)

FII

1.64%

Held by 5 FIIs

DII

0.12%

Held by 0 DIIs

Promoter

20.94%

Should I buy, sell or hold Vivimed Labs.?

22-Dec-2025

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Low ability to service debt as the company has a high Debt to EBITDA ratio of 12.57 times
The company has been able to generate a Return on Equity (avg) of 1.75% signifying low profitability per unit of shareholders funds

Negative results in Jun 23

Risky - No result in last 6 months

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 189 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

9.51

Return on Equity

-833.41%

Price to Book

5.04

Revenue and Profits:

Net Sales:

35 Cr

(Quarterly Results - Jun 2023)

Net Profit:

-16 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

99.74%

4 Years

15.19%

5 Years

23.98%

Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Vivimed Labs Hits Lower Circuit Amid Heavy Selling Pressure and Panic Selling

Vivimed Labs Ltd witnessed a sharp decline on 23 Dec 2025, hitting its lower circuit limit at ₹22.81, marking a maximum daily loss of 5.0%. The stock faced intense selling pressure, with panic selling dominating trade and leaving a significant portion of supply unfilled, reflecting a challenging trading session for this micro-cap pharmaceutical company.

Board Meeting Intimation for Notice Of Board Meeting / Closure Of Trading Window

28-Oct-2023 | Source : BSE

VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letter dated 30.09.2023 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday 14th Day of November 2023 at Hyderabad inter alia to consider and approve un-audited Financial Results (Standalone & Consolidated) of the company for the quarter and half year ended 30th September 2023. Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.10.2023 to till 48 hours after the declaration of un-audited Financial Results (Standalone & Consolidated) of the company for the quarter and half year ended 30th September 2023.

Notice Of 35Th Annual General Meeting (AGM) And Book Closure For AGM.

20-Oct-2023 | Source : BSE

AGM on November 132023 Book Closure: November 8 2023 to November 13 2023

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

20-Oct-2023 | Source : BSE

Certificate under Regulation 74(5)

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18

SPLITS

Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-32.46%

EBIT Growth (5y)

-213.27%

EBIT to Interest (avg)

-1.77

Debt to EBITDA (avg)

9.69

Net Debt to Equity (avg)

9.51

Sales to Capital Employed (avg)

0.64

Tax Ratio

0.64%

Dividend Payout Ratio

Pledged Shares

37.06%

Institutional Holding

1.76%

ROCE (avg)

-8.47%

ROE (avg)

1.75%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.04

EV to EBIT

-1.99

EV to EBITDA

-3.20

EV to Capital Employed

1.38

EV to Sales

3.33

PEG Ratio

Dividend Yield

ROCE (Latest)

-71.39%

ROE (Latest)

-833.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2023

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

37.0635

Mutual Funds

Held by 0 Schemes

FIIs

Held by 5 FIIs (1.64%)

Promoter with highest holding

Bbr Projects Private Limited (11.45%)

Highest Public shareholder

Kitara Piin 1102 (9.37%)

Individual Investors Holdings

56.71%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is -4.54% vs -33.57% in Mar 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is 94.14% vs -1,352.70% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.35",
          "val2": "37.03",
          "chgp": "-4.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.33",
          "val2": "-164.30",
          "chgp": "99.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "10.66",
          "val2": "8.52",
          "chgp": "25.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.58",
          "val2": "-265.99",
          "chgp": "94.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-0.93%",
          "val2": "-443.69%",
          "chgp": "442.76%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.33",
          "val2": "119.63",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.88",
          "val2": "0.31",
          "chgp": "-5,867.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.17",
          "val2": "18.12",
          "chgp": "0.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.23",
          "val2": "-25.63",
          "chgp": "-72.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.95%",
          "val2": "0.26%",
          "chgp": "-19.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.07",
          "val2": "176.15",
          "chgp": "-14.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.01",
          "val2": "-6.98",
          "chgp": "-229.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "27.39",
          "val2": "29.70",
          "chgp": "-7.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.54",
          "val2": "-49.31",
          "chgp": "-26.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.33%",
          "val2": "-3.96%",
          "chgp": "-11.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is -21.15% vs -72.46% in Mar 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is -385.63% vs 13.05% in Mar 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "187.10",
          "val2": "237.29",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-187.30",
          "val2": "-8.06",
          "chgp": "-2,223.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "35.90",
          "val2": "39.76",
          "chgp": "-9.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-328.53",
          "val2": "-67.65",
          "chgp": "-385.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-100.11%",
          "val2": "-3.40%",
          "chgp": "-96.71%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ

Jun'23

Mar'23

Change(%)

Net Sales

35.35

37.03

-4.54%

Operating Profit (PBDIT) excl Other Income

-0.33

-164.30

99.80%

Interest

10.66

8.52

25.12%

Exceptional Items

0.00

Consolidate Net Profit

-15.58

-265.99

94.14%

Operating Profit Margin (Excl OI)

-0.93%

-443.69%

442.76%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2023 is -4.54% vs -33.57% in Mar 2023

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2023 is 94.14% vs -1,352.70% in Mar 2023

All Quarterly Results

Half Yearly Results Snapshot (Consolidated) - Sep'22

Sep'22

Sep'21

Change(%)

Net Sales

94.33

119.63

-21.15%

Operating Profit (PBDIT) excl Other Income

-17.88

0.31

-5,867.74%

Interest

18.17

18.12

0.28%

Exceptional Items

0.00

Consolidate Net Profit

-44.23

-25.63

-72.57%

Operating Profit Margin (Excl OI)

-18.95%

0.26%

-19.21%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021

Consolidated Net Profit

Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021

All Half Yearly Results

Nine Monthly Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

150.07

176.15

-14.81%

Operating Profit (PBDIT) excl Other Income

-23.01

-6.98

-229.66%

Interest

27.39

29.70

-7.78%

Exceptional Items

0.00

Consolidate Net Profit

-62.54

-49.31

-26.83%

Operating Profit Margin (Excl OI)

-15.33%

-3.96%

-11.37%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021

Consolidated Net Profit

YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'23

Mar'23

Mar'22

Change(%)

Net Sales

187.10

237.29

-21.15%

Operating Profit (PBDIT) excl Other Income

-187.30

-8.06

-2,223.82%

Interest

35.90

39.76

-9.71%

Exceptional Items

0.00

Consolidate Net Profit

-328.53

-67.65

-385.63%

Operating Profit Margin (Excl OI)

-100.11%

-3.40%

-96.71%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2023 is -21.15% vs -72.46% in Mar 2022

Consolidated Net Profit

YoY Growth in year ended Mar 2023 is -385.63% vs 13.05% in Mar 2022

All Annual Results

Company CV

About Vivimed Labs Ltd

Vivimed Labs Ltd

Micro Cap

Pharmaceuticals & Drugs

Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

Company Coordinates

Company Details

Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403

Tel: 91-8482-232045

http://www.vivimedlabs.com

yugandhar.kopparthi@vivimeslabs.com

Registrar Details

Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad

Vivimed Labs.

1Day

52 Week

CASH

FII

DII

Promoter

Should I buy, sell or hold Vivimed Labs.?

MarketsMojo — Loved in India, Now Global

Dashboard

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Negative results in Jun 23

Risky - No result in last 6 months

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

Returns Beta

News

Vivimed Labs Hits Lower Circuit Amid Heavy Selling Pressure and Panic Selling

Announcements

Board Meeting Intimation for Notice Of Board Meeting / Closure Of Trading Window

Notice Of 35Th Annual General Meeting (AGM) And Book Closure For AGM.

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ

Half Yearly Results Snapshot (Consolidated) - Sep'22

Nine Monthly Results Snapshot (Consolidated) - Dec'22

Annual Results Snapshot (Consolidated) - Mar'23

About Vivimed Labs Ltd

Company Coordinates